H6D0:F:F-Haleon PLC (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 3.888

Change

+0.02 (+0.57)%

Market Cap

USD 34.71B

Volume

1.00K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRK:F Merck & Company Inc

+1.25 (+0.82%)

USD 66.78B
MRKC:F MERCK KGAA NAM.SP.ADR

+0.40 (+1.34%)

USD 65.62B
ZOE:F Zoetis Inc

-3.50 (-2.23%)

USD 64.18B
TKD:F Takeda Pharmaceutical Company ..

-0.43 (-1.75%)

USD 39.41B
TKDA:F Takeda Pharmaceutical Company ..

N/A

USD 38.72B
H6D:F Haleon PLC

+0.10 (+1.38%)

USD 35.12B
TEV:F Teva Pharmaceutical Industries..

+2.25 (+17.65%)

USD 14.69B
SH0:F Shionogi & Co. Ltd

+0.20 (+0.46%)

USD 12.76B
NB3:F Neurocrine Biosciences Inc

-0.60 (-0.46%)

USD 12.70B
RDDA:F Dr. Reddy's Laboratories Limit..

-3.00 (-4.35%)

USD 11.53B

ETFs Containing H6D0:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.71% 57% F 59% D-
Dividend Return 1.13% 18% F 38% F
Total Return 5.84% 54% F 57% F
Trailing 12 Months  
Capital Gain -0.36% 62% D 51% F
Dividend Return 1.54% 20% F 15% F
Total Return 1.18% 59% D- 47% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.54% 79% B- 64% D
Dividend Return 4.65% 74% C 58% F
Total Return 0.11% 3% F 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 8.65% 91% A- 84% B
Risk Adjusted Return 53.74% 90% A- 84% B
Market Capitalization 34.71B 98% N/A 95% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.